Sector Update: Health Care Stocks Decline Pre-Bell Friday
9:17AM ET 1/21/2022 MT NewswiresHealth care stocks were declining pre-bell Friday. The Health Care SPDR (XLV) was down 0.11% and the iShares NASDAQ Biotechnology Index (IBB) was recently...
Quotes Snapshot > ATHX
Athersys Inc ATHX:NASDAQ
Last Price$0.82NASDAQ Previous Close - Last Trade as of 3:57PM ET 1/26/22
Today's Change+0.005(0.60%)
Bid (Size)$0.76 (60)
Ask (Size)$0.93 (1)
Day Low / High$0.81 - 0.87
Volume1.2 M
Read more news Recent News
Athersys Appoints Chief Executive Officer
3:19AM ET 1/21/2022 MT NewswiresAthersys (ATHX) said Thursday that Daniel Camardo has been named chief executive officer, effective Feb. 14. Camardo will also join the company's board of...
--BofA Securities Downgrades Athersys to Neutral From Buy; Price Target is $1.25
10:03AM ET 11/19/2021 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
View all Commentary and Analysis
Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022
2:34PM ET 1/20/2022 Seeking AlphaAthersys: COVID-ARDS Is The Company's Most Important Target
6:44AM ET 11/25/2021 Seeking AlphaAthersys, Inc. (ATHX) CEO B.J. Lehmann on Q3 2021 Results - Earnings Call Transcript
11:07PM ET 11/15/2021 Seeking AlphaAthersys Shares Are Ready To Rumble Following Period Of Turmoil
2:46PM ET 8/30/2021 Seeking AlphaCompany Profile
Business DescriptionAthersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH. View company web site for more details
| Address | 3201 Carnegie Avenue Cleveland, Ohio 44115-2634 |
| Phone | +1.216.431.9900 |
| Number of Employees | 75 |
| Recent SEC Filing | 01/21/2022 8-K |
| President, Chief Executive & Operating Officer | William B. J. Lehmann |
| Chief Financial & Accounting Officer | Ivor MacLeod |
| Director, Chief Scientific Officer & Executive VP | John J. Harrington |
| Head-Information Technology & Communications | Rakesh Ramachandran |
Company Highlights
| Price Open | $0.82 |
| Previous Close | $0.82 |
| 52 Week Range | $0.75 - 3.03 |
| Market Capitalization | $193.1 M |
| Shares Outstanding | 235.2 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/24/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.41 |
| Beta vs. S&P 500 | N/A |
| Revenue | $24.3 M |
| Net Profit Margin | -1,442.59% |
| Return on Equity | -268.18% |
Analyst Ratings as of 11/18/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |